Workit Health has closed a $12 million Series B funding round led by FirstMark Capital, with participation from Lux Capital, GingerBread Capital, Blue Cross Blue Shield Venture Partners, and actor Rob Lowe. The investment brings the Ann Arbor-based virtual substance use disorder treatment provider’s total capital raised to $20 million and positions the company for geographic expansion as the pandemic accelerates adoption of telehealth models across behavioral health.
The December 2020 raise arrives at an inflection point for virtual addiction treatment delivery. While Workit has operated since 2015 with a thesis that medication-assisted treatment and therapy could be delivered effectively via telehealth platforms, COVID-19 has compressed what might have been years of gradual market acceptance into months of rapid adoption. The timing of this capital infusion suggests investors believe regulatory tailwinds and shifting patient preferences will outlast the pandemic emergency that catalyzed them.
Virtual MAT Delivery Finds Product-Market Fit
Workit’s model addresses persistent access barriers in traditional SUD treatment infrastructure. The company delivers care through mobile applications, offering interactive recovery curricula, video consultations, online peer support groups, and remote drug testing capabilities. By eliminating the need for patients to travel to brick-and-mortar facilities, the platform reduces logistical friction that often prevents individuals from initiating or maintaining treatment engagement.
The company currently provides MAT services in five states while offering therapy nationwide, treating thousands of patients with a team of approximately 150 clinical and operational staff. This bifurcated service footprint reflects the regulatory complexity that has historically constrained telehealth expansion in addiction medicine—MAT requires prescribing controlled substances, which faces state-specific licensing and practice requirements, while therapy services can scale more readily across state lines.
The strategic value proposition extends beyond patient convenience. Workit’s partnerships with health plans and employers signal recognition from payers that virtual delivery models can reduce total cost of care while improving outcomes through increased treatment engagement. For commercial payers facing rising medical costs associated with untreated substance use disorders, platforms that increase treatment initiation and retention offer compelling return on investment potential.
Competitive Positioning in Expanding Market
Workit operates in an increasingly crowded virtual behavioral health landscape where companies like Bicycle Health, Boulder Care, and others have also attracted venture capital to scale MAT delivery models. The competitive dynamic reflects both the massive addressable market—millions of Americans with opioid and alcohol use disorders lack access to evidence-based treatment—and the relatively early stage of telehealth penetration in addiction medicine compared to other medical specialties.
FirstMark Capital’s decision to lead this round provides insight into how investors are evaluating differentiation in this space. The firm’s portfolio focus on healthcare technology companies suggests they view Workit’s combination of clinical model, technology infrastructure, and operational execution as defensible in a market where clinical quality, regulatory compliance, and patient outcomes will increasingly separate winners from fast followers.
Blue Cross Blue Shield Venture Partners’ participation carries particular strategic significance. Health plan-affiliated venture arms typically invest with an eye toward portfolio companies that could eventually integrate into their parent organizations’ provider networks or demonstrate models worth replicating. BCBS VP’s involvement may signal validation that virtual MAT delivery aligns with broader payer strategies to expand access while managing costs.
Regulatory Environment Creates Expansion Opportunity
The company’s planned 2021 launch in Ohio, Texas, and Florida targets markets with substantial SUD treatment gaps and varying regulatory environments. Ohio has been particularly hard-hit by the opioid crisis and has implemented policies to expand MAT access, creating favorable conditions for telehealth providers. Texas represents a large, underserved market where geographic barriers have limited treatment availability, particularly in rural areas. Florida’s combination of high need and complex regulatory history in addiction treatment offers both opportunity and execution risk.
Workit’s expansion strategy must navigate the evolving patchwork of state telehealth regulations, DEA prescribing requirements, and licensure portability rules. The pandemic emergency triggered temporary regulatory flexibilities—including DEA allowances for initiating buprenorphine treatment via telehealth without initial in-person visits—that dramatically expanded what virtual providers could offer. The company’s growth trajectory will partly depend on whether these flexibilities become permanent or face rollback as emergency declarations expire.
Co-founder and co-CEO Robin McIntosh’s comments about “advocating for remote care for years” reflect the long-standing tension between clinical evidence supporting telehealth efficacy and regulatory frameworks designed for brick-and-mortar delivery. The company’s ability to demonstrate strong clinical outcomes while scaling operations could influence policy decisions about permanently expanding telehealth access for controlled substance prescribing.
Market Implications for Behavioral Health Delivery
Workit’s funding round exists within a broader transformation of behavioral health care delivery accelerated by the pandemic. The crisis has forced rapid adoption of technologies and care models that previously faced resistance from providers, payers, and regulators. Companies that can demonstrate sustained clinical quality and financial sustainability in this new environment position themselves as potential infrastructure for a fundamentally different treatment ecosystem.
The involvement of a celebrity investor like Rob Lowe—who has been public about his own recovery—highlights how SUD treatment is increasingly attracting mainstream attention and capital from sources beyond traditional healthcare investors. This reflects both destigmatization of addiction as a medical condition and growing recognition of the market opportunity in addressing unmet clinical need.
For traditional behavioral health providers, Workit’s growth trajectory poses strategic questions about how to respond to virtual competition. Health systems and specialty treatment centers that built infrastructure around in-person delivery models must decide whether to develop competing digital capabilities, partner with existing platforms, or defend their market position through clinical quality and comprehensiveness that virtual-first models cannot easily replicate.
The competitive dynamic between virtual-first platforms and traditional providers with digital offerings will likely vary by patient acuity and clinical complexity. Workit’s model appears optimized for patients appropriate for outpatient MAT and therapy, but may face challenges serving individuals requiring higher levels of care or those with complex co-occurring conditions requiring intensive intervention.
Strategic Outlook
As Workit deploys this capital to expand geographic footprint and clinical capacity, its execution will provide important market signals about the scalability of virtual SUD treatment models. Key metrics to monitor include patient retention rates, clinical outcomes compared to traditional delivery, payer reimbursement sustainability, and ability to serve diverse patient populations across socioeconomic and geographic segments.
The company’s success or challenges will influence how investors allocate capital across the behavioral health technology landscape and may shape regulatory decisions about permanent telehealth expansions. For an industry seeking to close the persistent gap between treatment need and treatment access, Workit’s growth represents a test case for whether technology-enabled delivery models can achieve meaningful scale while maintaining clinical quality and financial viability.
